Risk Mitigation, Identification, and OUD Treatment: Approaches to Conquering the Opioid Epidemic
When used and monitored appropriately, medication-assisted treatment (MAT) effectively:
A.) Reduces overdose-related deaths
B.) Helps individuals recover from opioid dependence
C.) Reduces the risk of infectious disease transmission
D.) All of the above
D. All of the above. When used and monitored appropriately, MAT effectively reduces overdose-related deaths, helps individuals recover from opioid dependence, and markedly reduces the risk of infectious disease transmission. However, many barriers hinder the utilization of MAT in practice.1-4
To learn how to overcome these barriers and to begin offering MAT to your patients with opioid use disorder, click the “Continue” button.
1. Volkow ND, et al. N Engl J Med. 2014;370:2063-66.
2. MacArthur GJ, et al. BMJ. 2012;345:e5945.
3. Tsai JI, et al. JAMA Intern Med. 2014;174:1974-81.
4. Jones CM, et al. Am J Pub Health. 2015;105:e55-63.
Edwin A. Salsitz, MD, DFASAM
Unit Chief Physician
Department of Psychiatry and Behavioral Sciences
Mount Sinai Beth Israel
Assistant Professor of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, NY
Glenn J. Treisman, MD, PhD
Eugene Meyer III Professor of Psychiatry and Medicine
Director of AIDS Psychiatry Service
Director of the Chronic Pain Treatment Program
Johns Hopkins University School of Medicine
Jaime Symowicz, PhD
Manager, Educational Strategy and Content
Lisa R. Rinehart, MS, ELS
Director, Editorial Services
Laura Muttini, RPh, MBA, CHCP
Chief Operating Officer
Kathryn Schaefer, MSN, RN
Lead Nurse Planner
East Lansing, MI
Upon completion, participants should be able to:
- Evaluate strategies to identify and counsel patients with OUD
- Individualize the treatment of patients with OUD by considering the latest clinical evidence as well as treatment- and patient-related factors
This activity is intended for primary care physicians, nurse practitioners, physician assistants, emergency department clinicians, and addiction specialists.
Series Overview/Statement of Need
Nonmedical prescription opioid and heroin use have reached epidemic proportions in the United States. Increasing access to and use of evidence-based medication-assisted treatments (MATs) in the management of opioid use disorder (OUD) is critically important. However, many barriers hinder the adoption of MAT, including misconceptions and stigma as well as tendencies to underestimate the risk of OUD and overdose. Although best practices and evidence-based guidelines exist to facilitate decisions about OUD treatment, strong evidence to support a specific algorithm is lacking and most frequently used guideline recommendations are outdated and do not include years of real-world clinical experience. By providing best-practice recommendations and current evidence regarding novel MAT formulations, clinicians will be able to better individualize OUD treatment.
Provided by Med-IQ. Powered by ProDoctor.
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions to Receive Credit
This CME activity consists of a 0.75-credit case simulation. To receive credit, read the introductory CME material, review the case simulation, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: April 30, 2018
Expiration Date: April 29, 2019
Estimated Time to Complete This Activity: 45 minutes
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Laura Muttini, RPh, MBA, CHCP
Ownership interest (stocks/stock options – excluding mutual funds): Abbott Laboratories, AbbVie Inc.
Edwin A. Salsitz, MD, DFASAM, has indicated no real or apparent conflicts.
Glenn J. Treisman, MD, PhD, has indicated no real or apparent conflicts.
The peer reviewers and other activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email email@example.com.
Microsoft Windows® 8, Windows 7
Mac OS 10.7 (Lion) or newer
Microsoft Internet Explorer 8.0 or later
Mozilla Firefox - latest version
Google Chrome - latest version
Apple Safari - latest version
Adobe Acrobat Reader® or Adobe Reader
Adobe Flash Player
Adobe Flash Player 9 or later
For technical support, go to http://www.med-iq.com/index.cfm?fuseaction=content.support
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: www.med-iq.com/privacy-statement/.
Acknowledgment of Commercial Support
This activity was funded in part by Coverys Community Healthcare Foundation, Inc., and supported by an educational grant from Indivior, Inc.
© 2018 Med-IQ, Inc.
The following material has been developed to accompany this activity:
Note: This material is not accredited for CME and, therefore, does not offer any CME/CE credit.
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.